Discontinued drugs in 2010: Cardiovascular drugs

Expert Opinion on Investigational Drugs

Volumn 20, Issue 10, 2011, Pages 1311-1325

  Zhao, Hong Ping ^a   Zhang, Xu Song ^a   Xiang, Bing Ren ^a  

^a CHINA PHARMACEUTICAL UNIVERSITY   (China)

Author keywords

Acadesine; Ataciguat; Atherosclerosis therapy Lilly 2; AZD 0837; AZD 1305; AZD 6482; Caldaret; Candesartan + pioglitazone; Darusentan; Eribaxaban; Fenofibrate + pravastatin; Fenofibrate + rosuvastatin 2; KRP 105; LCI 699; Piboserod; SAR 407899

Indexed keywords

5 AMINO 4 IMIDAZOLECARBOXAMIDE RIBOSIDE; ATACIGUAT; ATHEROSCLEROSIS THERAPY LILLY 2; AZD 0837; AZD 1305; AZD 6482; CALDARET; CANDESARTAN PLUS PIOGLITAZONE; CARDIOVASCULAR AGENT; DARUSENTAN; ENOXAPARIN; ERIBAXABAN; FASUDIL; FENOFIBRATE PLUS PRAVASTATIN; FENOFIBRATE PLUS ROSUVASTATIN; KETOCONAZOLE; KRP 105; LCI 699; PIBOSEROD; SAR 407899; UNCLASSIFIED DRUG; VERAPAMIL; WARFARIN;

ANGINA PECTORIS; ARTICLE; ATHEROSCLEROSIS; DOSE RESPONSE; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG INDICATION; DRUG RESEARCH; DRUG SAFETY; DRUG TARGETING; DRUG TOLERABILITY; HEART ARRHYTHMIA; HEART ATRIUM FIBRILLATION; HEART ATRIUM FLUTTER; HEART FAILURE; HEART INFARCTION; HUMAN; HYPERALDOSTERONISM; HYPERCHOLESTEROLEMIA; HYPERLIPIDEMIA; HYPERTENSION; HYPERTRIGLYCERIDEMIA; IMPOTENCE; NEUROPATHIC PAIN; NON INSULIN DEPENDENT DIABETES MELLITUS; PERIPHERAL VASCULAR DISEASE; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PULMONARY HYPERTENSION; REPERFUSION INJURY; SINGLE DRUG DOSE; THROMBOSIS; UNSPECIFIED SIDE EFFECT; VENOUS THROMBOEMBOLISM;

CARDIOVASCULAR AGENTS; CLINICAL TRIALS AS TOPIC; DRUG DISCOVERY; DRUGS, INVESTIGATIONAL; HUMANS; PRODUCT RECALLS AND WITHDRAWALS; UNITED STATES; UNITED STATES FOOD AND DRUG ADMINISTRATION;

EID: 80052762331     PISSN: 13543784     EISSN: 17447658     Source Type: Journal    
DOI: 10.1517/13543784.2011.611500     Document Type: Article

References (69)

1. Zhang XS, Xiang BR. Discontinued drugs in 2008: cardiovascular drugs. Expert Opin Investig Drugs 2009;18:875-85.
2. About us. Available from: http://www. pharmaprojects.com/about-us/[Last accessed 22 July 2011].
3. Bleeding time study with AZD6482, Clopidogrel and ASA. Available from: http://clinicaltrials.gov/ct2/show/NCT00853450?term=NCT00853450& rank=1 [Last accessed 29 July 2011]
4. Study to investigate safety and tolerability of a single dose of AZD6482. Available from: http://clinicaltrials.gov/ct2/show/NCT00688714? term=NCT00688714&rank=1 [Last accessed 29 July 2011]
5. Development pipeline. Available from: http://www.astrazeneca- annualreports.com/2010/additional-information/developmentpipeline. htm [Last accessed 22 July 2011]
6. Eli Lilly and Co. second quarter financial review July 22nd, 2010. Available from: http://lly.client.shareholder.com/common/download/download.cfm? companyid=LLY&fileid=388491& filekey=ecc503d1-ec98-4fbc-ab89- 65847d145557&filename= LLY-Q2-Presentation.pdf [Last accessed 22 July 2011]
7. Andersson B, Abi-Gerges N, Carlsson L. The combined ion channel blocker AZD1305 attenuates late Na current and IKr-induced action potential prolongation and repolarization instability. Europace 2010;12:1003-10
8. Clinical study report synopsis. Available from: http://www. astrazenecaclinicaltrials. com/-mshost800325/content/clinicaltrials/resources/ pdf/D3190C00005 [Last accessed 22 July 2011]
9. Clinical study report synopsis. Available from: http://www. astrazenecaclinicaltrials. com/-mshost800325/content/clinicaltrials/resources/ pdf/D3190C00009 [Last accessed 22 July 2011]
10. All discontinued products. Available from: http://www. astrazenecaclinicaltrials. com/other-drug-products/discontinuedproducts/AZD1305/ [Last accessed 22 July 2011]
11. Kawasumi H, Satoh N, Kitada Y. Caldaret, an intracellular Ca2+ handling modulator, limits infarct size of reperfused canine heart. J Pharmacol Sci 2007;103:222-33 (Pubitemid 46294655)
12. Bär FW, Tzivoni D, Dirksen MT, et al. Results of the first clinical study of adjunctive CAldaret (MCC-135) in patients undergoing primary percutaneous coronary intervention for ST-Elevation Myocardial Infarction: the randomized multicentre CASTEMI study. Eur Heart J 2006;27:2516-23 (Pubitemid 44627293)
13. Jang IK, Senatore F, Weisman N, et al. A randomized, double-blind, placebo-controlled study of the safety and efficacy of intravenous MCC-135 as an adjunct to primary percutaneous coronary intervention in patients with acute myocardial infarction. J Am Coll Cardiol 2007;49(Suppl A):1025-133
14. State of new product development. Available from: http://www.mt-pharma. co.jp/e/develop/pipeline/e-pipeline1003. pdf [Last accessed 22 July 2011]
15. Kohrt JT, Bigge CF, Bryant JW, et al. The discovery of (2R,4R)-N-(4-chlorophenyl)-N-(2-fluoro-4-(2-oxopyridin-1(2H)-yl)phenyl) -4-methoxypyrrolidine-1,2-dicarboxamide (PD 0348292), an orally efficacious factor Xa inhibitor. Chem Biol Drug Des 2007;70:100-12 (Pubitemid 47228656)
16. Mehta RS. Novel oral anticoagulants for prophylaxis and treatment of venous thromboembolism: part I (Factor Xa inhibitors). Expert Rev Hematol 2010;3:227-41
17. Squizzato A, Dentali F, Steidl L, et al. New direct thrombin inhibitors. Intern Emerg Med 2009;4:479-84
18. Xuan D, Boyd R, DiCarlo L. Population pharmacokinetics of pd 0348292, an oral, direct factor Xa inhibitor, in total knee replacement surgery patients. Clin Pharmacol Ther 2010;87:PII-47
19. Cohen AT, Armstrong D, Gazdzik T, et al. An adaptive-design dose-ranging study of PD 0348292, a new oral factor Xa inhibitor, for thromboprophylaxis after total knee replacement surgery [abstract 980]. American Society of Hematology Annual Meeting and Exposition; 2008
20. Products under development. Available from: http://www.kyorin-gr.co.jp/ en/ir/pdf/ar09/AR2009E12.pdf [Last accessed 22 July 2011]
21. Mid-term business plan. Available from: http://www.kyorin-gr.co.jp/en/ir/ pdf/20100512hope100.pdf [Last accessed 22 July 2011]
22. Hormonal and electrolyte responses to the aldosterone synthase inhibitor LCI699 in sodium depleted healthy subjects. Available from: http://www. abstractsonline.com/plan/ViewAbstract. aspx?mID=2444&sKey=24cca492-8584- 4d65-99e8-c1d717ed3985& cKey=3de2074e-335f-4b0a-a810-8282c0c2fd98&mKey= %7B7A9907EF-0B49-4421-A7AE-7E7F1EBB9402%7D [Last accessed 22 July 2011]
23. Novartis healthcare portfolio generates strong growth in first quarter of 2010, progress on delivering innovation, growth and productivity. Available from: http://www.novartis.com/newsroom/mediareleases/en/2010/1405499.shtml [Last accessed 22 July 2011]
24. Safety and efficacy of LCI699 in Cushing's disease patients. Available from: http://clinicaltrials.gov/ct2/show/NCT01331239? term=NCT01331239&rank= 1 [Last accessed 29 July 2011]
25. Form 20-F GlaxoSmithKline plc. Available from: http://www.gsk.com/ investors/reps04/20F-2004.pdf [Last accessed 29 July 2011]
26. A clinical study assessing the potential of Piboserod for the treatment of heart failure. Available from: http://clinicaltrials.gov/ct2/show/ NCT00421746? term=NCT00421746&rank=1 [Last accessed 29 July 2011]
27. Piboserod improves left-ventricular function in patients with symptomatic heart failure. Available from: http://www. docguide.com/piboserod-improves- leftventricular-function-patientssymptomatic-heart-failure [Last accessed 22 July 2011]
28. Product pipeline. Available from: http://www.serodus.com/product- pipeline/[Last accessed 22 July 2011]
29. Lohn M, Plettenburg O, Ivashchenko Y, et al. Pharmacological characterization of SAR407899, a novel rho-kinase inhibitor. Hypertension 2009;54:676-83
30. Press releases. Available from: http://en. sanofi.com/press/press- releases/2010/ppc-27174.asp [Last accessed 22 July 2011]
31. SAR407899 single-dose in treatment of mild to moderate erectile dysfunction. Available from: http://clinicaltrials.gov/ct2/show/NCT00914277? term= NCT00914277&rank=1 [Last accessed 29 July 2011]
32. Oberwittler H, Hirschfeld-Warneken A, Wesch R, et al. Significant pharmacokinetic and pharmacodynamic interaction of warfarin with the NO-independent sGC activator HMR1766. J Clin Pharmacol 2007;47:70-7 (Pubitemid 44974000)
33. Efficacy and safety study of Ataciguat versus placebo in patients with neuropathic pain. Available from: http://clinicaltrials.gov/ct2/show/ NCT00799656? term=NCT00799656&rank=1 [Last accessed 29 July 2011]
34. Epstein BJ. Efficacy and safety of darusentan: a novel endothelin receptor antagonist. Ann Pharmacother 2008;42:1060-9
35. Effect of ketoconazole on the pharmacokinetics of Darusentan in healthy subjects. Available from: http://www.aapsj.org/abstracts/AM-2009/AAPS2009- 003551.PDF [Last accessed 22 July 2011]
36. DORADO-fixed doses of Darusentan as compared to placebo in resistant hypertension. Available from: http://clinicaltrials.gov/ct2/show/NCT00330369? term=NCT00330369& rank=1 [Last accessed 29 July 2011]
37. Second pivotal phase III study of Gilead's Darusentan for resistant hypertension misses primary endpoints. Available from: http://www.gilead.com/pr- 1365747 [Last accessed 22 July 2011]
38. Gilead sciences announces record fourth quarter and full year 2009 financial results. Available from: http://www. gilead.com/pr-1379225 [Last accessed 22 July 2011]
39. Blopress + Actos combination enters PIII. Available from: http://www. accessmylibrary.com/article-1G1-207694031/blopress-actos-combinationenters. html [Last accessed 29 July 2011]
40. Company pipeline. Available from: http://www.takeda.com/pdf/usr/default/ 11-1-37769-2.pdf [Last accessed 22 July 2011]
41. Product pipeline. Available from: http://www.takeda.com/pdf/usr/default/ 11-40972-2.pdf [Last accessed 22 July 2011]
42. Johansson S, Cullberg M, Eriksson UG, et al. Single-dose pharmacokinetics, pharmacodynamics and safety of AZD0837, a novel oral direct thrombin inhibitor, in young healthy male subjects. Int J Clin Pharmacol Ther 2011;49:258-67
43. Atrial fibrillation patients not taking vitamin-K antagonist. Available from: http://clinicaltrials.gov/ct2/show/NCT00623779?term=NCT00623779& rank=1 [Last accessed 29 July 2011]
44. Prevention of stroke and systemic embolic events in patients with atrial fibrillation. Available from: http://clinicaltrials.gov/ct2/show/NCT00684307? term=NCT00684307& rank=1 [Last accessed 29 July 2011]
45. AstraZeneca development pipeline 29 January 2009. Available from: http://www.astrazeneca.se/-mshost9752227/content/resources/gUserfiles/10540506 [Last accessed 22 July 2011]
46. Abbott and AstraZeneca announce collaboration to develop and commercialize CRESTOR(R) and next-generation TriCor(R) (ABT-335) fixed-dose combination. Available from: http://www.prnewswire.com/newsreleases/abbott-and- astrazeneca-announcecollaboration-to-develop-andcommercialize-crestorr-and- nextgeneration-tricorr-abt-335-fixed-dosecombination-55793347.html [Last accessed 22 July 2011]
47. Martin PD, Dane AL, Schneck DW, et al. An open-label, randomized, three-way crossover trial of the effects of coadministration of rosuvastatin and fenofibrate on the pharmacokinetic properties of rosuvastatin and fenofibric acid in healthy male volunteers. Clin Ther 2003;25:459-71 (Pubitemid 36286913)
48. A year 2, safety extension study of the combination of ABT-335 and statin therapy for subjects with mixed dyslipidemia. Available from: http://clinicaltrials.gov/ct2/show/NCT00491530?term=NCT00491530& rank=1 [Last accessed 29 July 2011]
49. Study to evaluate the long-term safety and efficacy of ABT-335, in combination with three different statins in subjects with mixed dyslipidemia. Available from: http://clinicaltrials.gov/ct2/show/NCT00300430?term= NCT00300430& rank=1 [Last accessed 29 July 2011]
50. Evaluate safety and efficacy of ABT-335 in combination with Rosuvastatin calcium in subjects with multiple abnormal lipid levels in the blood. Available from: http://clinicaltrials.gov/ct2/show/NCT00300482?term=NCT00300482& rank=1 [Last accessed 29 July 2011]
51. AstraZeneca and Abbott submit new drug application to the FDA for the approval of CERTRIAD for the treatment of mixed dyslipidemia. Available from: http://www.astrazeneca. com/Media/Press-releases/Article/20090604-AstraZeneca- and-Abbott-Submit-New-Drug-Application-to [Last accessed 22 July 2011]
52. A FDA report regarding Trilipix indication for coadministration with a statin in May 2011. Available from: http://www.fda.gov/downloads/ AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/EndocrinologicandMetabolic DrugsAdvisoryCommittee/UCM261163. pdf [Last accessed 22 July 2011]
53. AstraZeneca and Abbott end license agreement for the development of Certriad. Available from: http://www. astrazeneca.com/Media/Press-releases/ Article/AstraZeneca-ends-agreement-with-Abbott-for-Certriad [Last accessed 22 July 2011]
54. PeriCor Therapeutics announces closing of licensing agreement for Acadesine with schering-plough corporation. Available from: http://www. pericortherapeutics. com/pdf/070820-PeriCor-SP-press-release-Final.pdf [Last accessed 22 July 2011]
55. Dixon R, Gourzis J, McDermott D, et al. AICA-riboside: safety, tolerance, and pharmacokinetics of a novel adenosine-regulating agent. J Clin Pharmacol 1991;31:342-7
56. The effect of Acadesine on reducing cardiovascular and cerebrovascular adverse events in coronary artery bypass graft surgery (Study P05633AM1) (TERMINATED) (RED-CABG). Available from: http://clinicaltrials.gov/ct2/show/ NCT00872001? term=NCT00872001&rank=1 [Last accessed 29 July 2011]
57. Form 10-q. Available from: http://www. sec.gov/Archives/edgar/data/ 310158/000095012310074336/y83714e10vq.htm [Last accessed 22 July 2011]
58. A study to evaluate daily Pravastatin, Fenofibrate or Pravafen in the treatment of combined hyperlipidemia. Available from: http://clinicaltrials.gov/ ct2/show/NCT00459745?term=NCT00459745& rank=1 [Last accessed 29 July 2011]
59. Financial results for the third quarter of fiscal year 2009. Available from: http://www.shionogi.co.jp/ir-en/materials/detail/con10-02.pdf [Last accessed 22 July 2011]
60. 1 half of fiscal 2010 financial results. Available from: http://www.shionogi.co. jp/ir-en/explanatory/pdf/e-p101102.pdf [Last accessed 22 July 2011]
61. Meeting highlights from the committee for medicinal products for human use. Available from: http://www.ema.europa. eu/docs/en-GB/document-library/ Press-release/2011/01/WC500101076. pdf [Last accessed 22 July 2011]
62. Marchetti S, Schellens JH. The impact of FDA and EMEA guidelines on drug development in relation to Phase 0 trials. Br J Cancer 2007;97:577-81 (Pubitemid 47339894)
63. Branca MA. Academia given a helping hand in drug development. Nat Rev Drug Discov 2006;5:177 (Pubitemid 43336026)
64. Sugiyma Y, Yamashita S. Impact of microdosing clinical study-why necessary and how useful? Adv Drug Deliv Rev 2011;63:494-502.
65. Schäfer S, Kolkhof P. Failure is an option: learning from unsuccessful proof-of-concept trials. Drug Discov Today 2008;13:913-16.
66. Czerepak EA, Ryser S. Drug approvals and failures: implications for alliances. Nat Rev Drug Discov 2008;7:197-8 (Pubitemid 351321230)
67. About 'MetaDrug'. Available from: http://www.genego.com/metadrug.php [Last accessed 22 July 2011].
68. Drabu S, Gupta A, Bhadauria A. Emerging trends in contract research industry in India. Contemp Clin Trials 2010;31:419-22
69. Kanavos P. A prospective view on European pharmaceutical research and development-Policy options to reduce fragmentation and increase competitiveness. Pharmacoeconomics 1998;13:181-90 (Pubitemid 28081909)